493

Compound name
Asciminib
Alt Name
ABL-001
ABL001
Compound Image
Asciminib.png
SMILES
C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4
MW
449.80
Brutto
C20H18ClF2N5O3
InChI
InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1
InChI Key
VOVZXURTCKPRDQ-CQSZACIVSA-N
Approval Jurisdiction
2021 FDA
Approved for clinical use
Chronic Myelogenous Leukemia
CAS
1492952-76-7
PubChem CID
72165228
Action
Bcr-ABL
Approved Drug List
1
Commercial Vendor
Novartis